What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class II recall involving a specific prescription cancer medication known as PEMRYDI RTU. This product is a ready-to-use injection of pemetrexed, supplied in single-dose vials with a concentration of 100 mg per 10 mL (equivalent to 10 mg/mL). The medication is intended for intravenous administration and carries an Rx-only designation, meaning it is strictly available by prescription from a healthcare provider. The recall specifically targets vials manufactured by Zydus Lifesciences Limited, located in Ahmedabad, India, and distributed across the United States by Amneal Pharmaceuticals LC in Bridgewater, New York.
To accurately identify whether you possess the affected product, you must verify several critical details on the packaging. The recalled items bear the National Drug Code (NDC) number 70121-2453-1. Two specific lot numbers are implicated in this recall: P400172 and PA00050A. It is important to note that the expiration date for these affected lots is September 30, 2027. Because PEMRYDI RTU is a sterile injectable used in clinical oncology settings, precise lot verification is essential, as other lots from different manufacturing dates may not be subject to this specific action.
This recall was initiated on July 29, 2026, following market complaints that reported visible discoloration in certain vials. The affected solution appeared green to dark green, a deviation from the expected clear or nearly clear appearance of pemetrexed injection. While the distribution pattern for this product is nationwide across the USA, making it difficult to pinpoint exact geographic boundaries without lot-specific data, the scope covers all units bearing the identified NDC and lot numbers that were distributed by Amneal Pharmaceuticals. The classification as a Class II recall indicates that use of or exposure to the defective product may cause temporary health problems or pose slight threat of serious nature, but is not expected to cause serious adverse health consequences or death.
If you are a patient currently undergoing treatment with PEMRYDI RTU, or if you are a healthcare provider managing oncology care, it is vital to cross-reference your current inventory against the lot numbers P400172 and PA00050A. The manufacturer, Zydus Lifesciences Limited, and the distributor, Amneal Pharmaceuticals LC, are the entities responsible for this product line. However, the official recall notice does not currently state a specific remedy, such as a return or replacement process, leaving patients and providers to consult their healthcare facilities and distributors for immediate next steps regarding affected stock.
The hazard, explained
At first glance, a vial of medication is supposed to look like a uniform, clear liquid. When that clarity breaks down and the solution turns green or dark green, it signals a fundamental failure in the product’s stability. This discoloration is not merely an aesthetic issue; it is a visible chemical red flag indicating that the pemetrexed injection has degraded. Pemetrexed is a potent chemotherapy drug used to treat certain types of cancer, including lung and ovarian cancers. Because it works by interfering with how cells create DNA and RNA, its molecular structure must remain precise to function safely and effectively within the body.
When a sterile injectable solution changes color, it typically means that the active pharmaceutical ingredient or one of its inert components has undergone oxidation or hydrolysis due to environmental stress, improper storage, or a manufacturing defect. In the case of this recall by Shilpa Medicare Limited and distributed by Amneal Pharmaceuticals, the specific hazard is the presence of green discoloration in certain single-dose vials of PEMRYDI RTU (pemetrexed injection), 100 mg/10 mL. The FDA has classified this as a Class II recall, which indicates that use or exposure to the product might cause temporary health problems or pose a slight threat of a serious nature, though it is not immediately life-threatening in the same way a Class I recall for a contaminated syringe might be.
The danger here lies in two main areas: efficacy and safety. First, if the drug has degraded, it may no longer contain the full amount of pemetrexed indicated on the label. For a cancer patient relying on this chemotherapy to shrink tumors or prevent recurrence, receiving a sub-potent dose is critically dangerous. It could allow the disease to progress unchecked during a vital treatment window. Second, the chemical byproducts created by this degradation are unknown and potentially harmful. Injecting degraded compounds into your bloodstream can trigger unexpected immune responses, severe allergic reactions, or local tissue damage at the injection site.
It is also important to understand why this matters even if the vial looks slightly off. Pemetrexed injections are administered directly into the vein (intravenously) or muscle (intramuscularly). Unlike a pill you might throw away if it looks weird, an IV bypasses your body’s natural filters in the stomach. Any particulate matter or altered chemical state enters your circulation immediately. While the FDA report does not currently list any incidents of injury, the potential for harm exists because patients cannot see inside the glass vial until they are ready to draw the medication. By then, it may be too late. This is why the visual cue of green discoloration is so critical—it is your only early warning system before the drug enters your body.
Furthermore, pemetrexed is highly sensitive to pH levels and temperature. If the manufacturing process did not strictly control these variables, or if the vial’s seal was compromised during distribution from Zydus Lifesciences in India to the U.S., the solution becomes vulnerable to rapid chemical breakdown. The green hue suggests a reaction that has progressed beyond the initial stages of instability. For a patient undergoing rigorous chemotherapy schedules, maintaining the integrity of every dose is essential. A degraded dose not only fails its therapeutic job but may also introduce toxic impurities into your system, compounding the side effects already common with this class of drug.
Who is most at risk
To understand who is truly at risk in this situation, we first need to look at what PEMRYDI RTU actually is and who typically handles it. This is not a product you will find on a pharmacy shelf for over-the-counter purchase. It is a prescription-only medication, specifically a chemotherapy drug known as pemetrexed. Because of its powerful nature, it is designed to treat serious conditions, most commonly non-small cell lung cancer and malignant pleural mesothelioma. This immediately narrows the group of people who could potentially be affected: individuals who are actively undergoing cancer treatment. The "RTU" in the name stands for "Ready-to-Use," meaning the drug comes pre-mixed and ready to be administered by a healthcare professional, rather than needing to be compounded by a pharmacist.
The primary risk is not to the general public, but specifically to the patients who are scheduled to receive an infusion of this exact medication. The hazard here is a discolored solution—specifically, vials that have turned from their clear, colorless state to green or dark green. While you might think that seeing a different color would be an obvious stop-sign for a nurse or doctor, medical professionals often work under high pressure and tight schedules. If the discoloration is subtle, or if the lighting in an infusion center is bright and clinical, it is possible for a compromised vial to pass visual inspection. Therefore, the patient receiving the injection is the person most directly at risk of harm. Administering a discolored injectable drug can introduce unknown chemical byproducts or degradation products into the bloodstream, potentially leading to adverse reactions that were not part of the original treatment plan.
It is also important to consider who handles these vials before they reach the patient. The recall affects vials distributed nationwide, meaning any hospital, clinic, or oncology center across the United States could potentially have this specific lot on their shelves. This puts healthcare workers, nurses, and pharmacists at a secondary risk of exposure to contaminated product during preparation or administration. However, the greatest vulnerability remains with the patient population receiving chemotherapy. These individuals are often already dealing with weakened immune systems due to their cancer diagnosis or other medications they are taking. Their bodies may be less able to tolerate unexpected side effects from a compromised drug product compared to a healthy individual. If a discolored vial is used, the patient might experience an allergic reaction, tissue damage at the injection site, or systemic toxicity that complicates their ongoing care.
You should also be aware of the distribution pattern. Since this recall covers nationwide distribution, there is no geographic area where you are automatically safe from having one of these vials in your local medical facility. The risk is tied entirely to your specific treatment schedule and the inventory of your healthcare provider, not your location. If you or a loved one is scheduled for pemetrexed treatment, it is crucial to verify the lot numbers with your care team immediately, regardless of where you live.
How to tell if you have the recalled item
If you or a loved one has been prescribed PEMRYDI RTU (pemetrexed injection) for cancer treatment, knowing exactly which vials are affected is critical to your safety. Because this recall involves a specific batch of medication with a visible defect, it is important to verify the details carefully before taking any action. The process begins by locating the label on the single-dose vial. You should not rely solely on memory or general packaging boxes; the definitive information is printed directly on the glass container itself.
First, confirm that you have the correct brand and manufacturer. The recalled product is PEMRYDI RTU, manufactured by Zydus Lifesciences Limited in Ahmedabad, India, and distributed by Amneal Pharmaceuticals LC in Bridgewater, New York. Ensure the label clearly states "Rx only" and indicates the strength is 100 mg/10 mL (which equals 10 mg/mL). This medication is a prescription drug used for specific cancer treatments, so if you have been receiving regular infusions, this is the product to check.
The most crucial step is checking the National Drug Code (NDC) and the Lot numbers. The recall applies specifically to NDC 70121-2453-1. Look for one of the following lot numbers printed on the vial label: P400172 or PA00050A. If your vial has a different lot number, it is not part of this specific recall event. Additionally, check the expiration date. The recalled lots have an expiration date of September 30, 2027 (09/30/2027). While the expiration date helps confirm you have the right product type, the Lot number is the primary identifier for exclusion or inclusion in this recall.
Finally, inspect the physical appearance of the solution inside the vial. The reason for this recall is that certain vials contain a discolored solution. Specifically, look for any green to dark green discoloration in the liquid. A clear, colorless, or slightly yellowish solution is typical for pemetrexed injection. If you see any shade of green, do not use the vial under any circumstances. This visual defect indicates a potential chemical instability that could affect the safety and efficacy of the drug.
If you are unsure whether your medication matches these criteria, contact your healthcare provider or pharmacist immediately. They can access their inventory records to verify the lot numbers and NDC codes for all medications currently on hand at their facility. Do not attempt to identify the product by price or purchase date alone, as these factors do not determine safety status. Only the combination of the correct NDC, specific Lot numbers, and the visible discoloration confirms whether your PEMRYDI RTU vial is part of this Class II recall.
What to do — step by step
If you or someone you care for currently possesses the Shilpa Medicare Limited PEMRYDI RTU (pemetrexed injection) products identified in this recall, it is critical to act with both urgency and calm precision. Because the specific remedy details were not explicitly stated in the official FDA announcement, you must rely on standard pharmaceutical safety protocols for Class II recalls involving injectable medications. Your immediate goal is to prevent any further use of potentially compromised medication while establishing a clear paper trail with the distributors. Please follow these steps carefully.
- Stop using the product immediately. If you have not yet administered the injection, do not start. The hazard involves a green to dark green discoloration in certain vials, which indicates a potential stability or contamination issue. Even if the solution appears clear in some lighting, you should not use it based on lot number alone until you receive specific clearance from your healthcare provider. If you are currently undergoing treatment with this drug, contact your oncologist or infusion nurse right away to discuss alternative dosing schedules or replacement supplies.
- Identify and isolate the specific vials. Retrieve any boxes or vials corresponding to the recalled items. You are looking for PEMRYDI RTU (pemetrexed injection), 100 mg/10 mL, manufactured by Zydus Lifesciences Limited and distributed by Amneal Pharmaceuticals LC. Specifically, check for NDC 70121-2453-1 with Lot numbers P400172 or PA00050A. Place these items in a safe, secure location away from family members, pets, and general access points to prevent accidental administration. Do not attempt to inspect the solution inside for discoloration if you are unsure how to handle it safely; let the visual cues provided by your pharmacist guide you.
- Contact your pharmacy or healthcare provider. This is the most vital step because the official remedy was not stated in the initial recall notice. Call the pharmacy where you filled the prescription or the clinic where you receive your infusion therapy. Inform them that you have a vial from Lot P400172 or PA00050A. They will verify the status of the stock and guide you on whether to return the unused vials to their facility or if they will coordinate a direct pickup with the distributor, Amneal Pharmaceuticals LC.
- Do not dispose of the medication in household trash. Used or unused injectable medications require special disposal methods to ensure environmental safety and prevent misuse. Your pharmacy or healthcare provider can direct you to local drug take-back programs or provide specific hazardous waste disposal instructions. If you cannot reach them immediately, keep the vials in their original packaging, sealed in a plastic bag, to maintain integrity until proper disposal can be arranged.
- Report any adverse experiences. If you have already used a vial from this lot and experience any unusual symptoms, or if you suspect a reaction related to the discoloration hazard, report it to your doctor immediately. You may also file a voluntary report with the FDA’s MedWatch program online or by phone. This helps regulatory agencies monitor the real-world impact of the recall.
Remember, while this is a Class II recall—indicating that use of the product might cause temporary or medically reversible health consequences—the uncertainty surrounding the specific remedy means you must prioritize direct communication with your medical team. They are your best resource for navigating the replacement process and ensuring your treatment plan remains uninterrupted.
Your refund, repair, or replacement options
When a pharmaceutical product is recalled, the most immediate concern for patients and healthcare providers is often: "What do I do with the medication, and will I get my money back?" In this specific instance involving Shilpa Medicare Limited’s PEMRYDI RTU (pemetrexed injection), the official recall notice from the FDA does not explicitly state the remedy. This means that standard terms such as a full refund, a direct replacement vial, or a repair option are not outlined in the public record we have access to. It is important to understand why this happens: Class II recalls, like this one, typically involve products that might cause temporary health problems or pose a slight threat of serious injury, rather than those that are immediately life-threatening. Because the hazard here is a visual defect—discolored solution ranging from green to dark green—the primary focus of the recall is on preventing the administration of the compromised drug, not necessarily on immediate financial restitution for every single vial.
However, the absence of a stated remedy in the general recall description does not mean you are left without recourse. The responsibility for handling the disposition of these products generally falls on the supply chain entities involved: Amneal Pharmaceuticals LC, the distributor, and Shilpa Medicare Limited, the manufacturer. If you are a patient who has already purchased this medication, your path to resolution will likely involve contacting your pharmacy or healthcare provider rather than the manufacturer directly. Pharmacies typically handle the return of recalled drugs through their wholesale distributors. In this case, that would be Amneal Pharmaceuticals LC in Bridgewater, NY. They have established protocols for returning Class II recalled items. You should not attempt to dispose of these vials in your household trash or sewage system under any circumstances, as improper disposal can pose environmental and safety risks.
If you are a healthcare facility, such as a hospital or clinic, that currently stocks this product, the process is more structured. You must isolate the affected lots immediately. The specific lots involved are P400172 and PA00050A, which expire on 09/30/2027. These vials should be quarantined in a secure area to prevent accidental administration. Your procurement or pharmacy department should then contact Amneal Pharmaceuticals LC directly to initiate the return process. While the recall notice does not specify whether you will receive credit for the returned goods, it is standard industry practice for distributors to issue credits or replacements for recalled pharmaceuticals that have not yet been administered. This ensures that your treatment plan is not disrupted unnecessarily.
For patients who are unsure of their status, the first step is to verify if you possess the product by checking the NDC 70121-2453-1 and the lot numbers mentioned above. If you do have these vials, contact your pharmacist immediately. They can confirm whether they have received instructions from Amneal regarding returns or credits. It is crucial to act promptly, not just for financial reasons, but because the discolored solution indicates a potential stability issue that could affect the drug's efficacy or safety. By following the chain of distribution back to the distributor, you ensure that the product is handled correctly and that any available compensation or replacement options are processed according to company policy.
What can happen if you ignore it
When a pharmaceutical product like PEMRYDI RTU is recalled due to visible changes in its physical appearance, such as the green to dark green discoloration reported by Shilpa Medicare Limited, the primary concern is not just aesthetic but chemical and biological. Pemetrexed injection is a potent chemotherapy medication used to treat certain types of cancer, including non-small cell lung cancer and mesothelioma. Because it is administered directly into the body, typically via intravenous infusion, the integrity of the solution is paramount. Ignoring this recall and continuing to use or administer a discolored vial introduces several serious risks that go beyond simple product defects.
The most immediate danger stems from the uncertainty of what has caused the discoloration. In pharmaceutical chemistry, a change in color often indicates that the active ingredient—pemetrexed—may have degraded, oxidized, or reacted with the container material or other components within the vial. If the drug has broken down, it may no longer be effective at killing cancer cells, leading to treatment failure. For patients undergoing rigorous chemotherapy regimens, even a slight reduction in efficacy can allow the disease to progress unchecked, potentially compromising the entire course of therapy and reducing the chances of successful outcomes.
Equally concerning is the potential formation of harmful byproducts. When chemical stability is compromised, new compounds may form that are toxic or irritating to human tissue. Injecting a solution containing unknown degradation products can cause severe local reactions at the injection site, such as intense pain, swelling, necrosis (tissue death), or phlebitis (inflammation of the vein). More systemically, these impurities could trigger allergic reactions, anaphylaxis, or other adverse immune responses that were not anticipated with the pure, intended medication. The FDA’s classification of this as a Class II recall suggests that while use of the product is not likely to cause serious adverse health consequences or death, it could result in temporary medical problems or require corrective action, underscoring the need for caution.
Furthermore, using a compromised drug disrupts the careful balance of your treatment plan. Chemotherapy dosing is calculated precisely based on body surface area and kidney function to maximize benefit while minimizing toxicity. Introducing an unknown variable like a degraded drug throws this balance off. You might receive less medication than needed, or conversely, if the concentration has altered unpredictably, you might be exposed to higher levels of impurities. This uncertainty places your health at unnecessary risk when a simple verification step could prevent it.
Finally, there is the logistical and emotional toll. If you continue to use the recalled lot and experience an adverse event, untangling whether it was caused by the drug’s degradation or the underlying cancer progression becomes complex for your healthcare provider. This can delay necessary adjustments to your care plan. Rather than risking your health on a vial that has been flagged for potential instability, take the time to verify your lot numbers against the official recall notice. Your safety and the effectiveness of your cancer treatment depend on the reliability of every component in your care.